Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas

被引：4
作者：
Vassilakopoulos T.P. [1 ]
Prassopoulos V. [2 ]
Rondogianni P. [3 ]
Chatziioannou S. [4 ]
Konstantopoulos K. [1 ]
Angelopoulou M.K. [1 ]
机构：
[1] Department of Haematology, School of Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 17 Agiou Thoma Str., Goudi, Athens
[2] Department of Nuclear Medicine and PET/CT, HYGEIA Hospital, 20 Pefkon Str., AgiosStefanos, Athens
[3] Department of Nuclear Medicine and PET/CT, Evangelismos General Hospital, 45–47 Ipsilantou Str., Athens
[4] Centre for Clinical and Translational Research, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, Athens
来源：
memo - Magazine of European Medical Oncology | 2015年 / 8卷 / 2期
关键词：
Diffuse large B-cell lymphoma; Hodgkin lymphoma; Interim PET; PET; PET/CT; Primary mediastinal large B-cell lymphoma;
D O I：
10.1007/s12254-015-0215-7
中图分类号：
学科分类号：
摘要：
Positron emission tomography with integrated computed tomography (PET/CT) is increasingly used for the initial staging, final or even interim (mid-treatment) response assessment in malignant lymphomas. Extensive clinical experience has been gained with Hodgkin lymphoma (HL) and aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMLBCL) and other subtypes, which are the subject of the present review. The use of PET/CT is now considered mandatory for baseline staging in these entities, providing more accurate information and obviating the need of bone marrow biopsy (BMB) at least in HL. PET/CT has been the long-standing “gold standard” for final response assessment. Furthermore, early interim PET evaluation provides valuable prognostic information in HL and DLBCL. In HL, it appears that treatment intensification with Bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP)-escalated can improve disease control in patients with persistent PET positivity after two cycles of ABVD. However, there is no randomized evidence of survival benefit as yet. In contrast, regimens effective in overcoming the adverse impact of persistent PET positivity have not been yet described in DLBCL. The 2014 recommendations suggest the use of PET/CT for baseline staging and final response assessment in all [18F]fluorodeoxyglucose (FDG)-avid lymphoma subtypes, including the above named ones. The use of interim evaluation is not considered fully documented yet. The exact role of PET/CT in guiding treatment decisions has to be defined by ongoing and future randomized trials and evidence-based approaches are expected to become available in the near future. © 2015, Springer-Verlag Wien.
引用
收藏
页码：105 / 114
页数：9
相关论文
共 76 条
  • [1] Cheson B.D., Pfistner B., Juweid M.E., Revised response criteria for malignant lymphoma, J Clin Oncol, 25, pp. 579-586, (2007)
  • [2] Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Lister T.A., Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, pp. 3059-3067, (2014)
  • [3] Barrington S.F., Mikhaeel G.N., Kostakoglu L., Meignan M., Hutchings M., Mueller S.P., Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J Clin Oncol, 32, pp. 3048-3058, (2014)
  • [4] Hutchings M., Hematology 2012, Am Soc Hematol Educ Programm Book, pp. 322-327, (2012)
  • [5] Sehn L.H., Klasa R., Shenkier T., Villa D., Slack G.W., Gascoyne R.D., Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP, Hematol Oncol, 31, S1, (2013)
  • [6] Pfreundschuh M., Trumper L., Osterborg A., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, Lancet Oncol, 7, pp. 379-391, (2006)
  • [7] Pfreundschuh M., Schubert J., Ziepert M., Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60), Lancet Oncol, 9, pp. 105-116, (2008)
  • [8] Paone G., Itti E., Haioun C., Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate, Eur J Nucl Med Mol Imaging, 36, pp. 745-750, (2009)
  • [9] Vassilakopoulos T.P., Pangalis G.A., Katsigiannis A., Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care, Oncologist, 17, pp. 239-249, (2012)
  • [10] Martelli M., Ceriani L., Zucca E., Zinzani P.L., Ferreri A.J., Vitolo U., [<sup>18</sup>F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study, J Clin Oncol, 32, pp. 1769-1775, (2014)
12345678